3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
10
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Carcinoma, Transitional Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Melanoma
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Lymphoma, Follicular
2
Lymphoma
2
Central Nervous System Neoplasms
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Mycosis Fungoides
1
Metastatic Urothelial Cell Cancer
1
Metastatic Solid Tumors
1
Interventions
Gemcitabine
4
pembrolizumab
3
enfortumab vedotin
2
Specimen Handling
2
vinflunine
1
erdafitinib
1
enzalutamide
1
cabozantinib
1
avelumab
1
abexinostat
1
Sorafenib
1
Ramucirumab
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Ipilimumab
1
Everolimus
1
Doxorubicin
1
Cisplatin
1
Carboplatin
1
CTLA-4 Antigen
1
Bortezomib
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Ureteral Neoplasms
×
avelumab
×
Clear all
NCT04004442
2026-03-13
COAXIN
University of Oklahoma
Phase 1
Active not recruiting
19 enrolled